drugset
drugset / Trial / NCT02776215

Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

NCT02776215 ↗

Phase 1 Completed 24 enrolled Vanda Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents.

Timeline

Start
2016-10-04
Primary completion
2017-12-20
Completion
2017-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject tasimelteon Small molecule — —

Indications

Smith-Magenis syndrome autism spectrum disorder non-24-hour sleep-wake syndrome